Retrospective comparison of chemotherapy-induced myelotoxicity in patients with ovarian cancer under and over 60 years of age

Journal of Chemotherapy

Volumn 18, Issue 6, 2006, Pages 656-661

  Peintinger, Florentia ^a   Georgoulopoulos, A ^b   Ralph, G ^a   Piswanger, C ^c  

^a General Hospital of Leoben   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Myelotoxicity; Older patients; Ovarian cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NEUTROPENIA; OVARY CANCER; THROMBOCYTOPENIA;

EID: 33845995071     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.6.656     Document Type: Article

References (27)

1. http://seer.cancer.gov/csr/1975 2000/results merged/sect_20_ovary.pdf
2. http://www-dep.iarc.fr/eucan.htm
3. National Comprehensive Cancer Network, Clinical practice guidelines in oncology-v.1. 2005: 101-102.
4. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-1691.
5. Ozols RF. Optimum chemotherapy for ovarian cancer. Int J Gynecol Cancer 2000;10:33-37.
6. Muggia FM, Braly PS, Brady MF et al: Phase III randomized study of cisplatin versus paclitaxel in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106-115.
7. Du Bois A, Lueck HJ, Meier W et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as firstline treatment in ovarian cancer. J Natl Cancer Inst 2003;95:1320-1329.
8. McGuire WP III and Markman M. Primary ovarian cancer chemotherapy: current standard of care. Br J Cancer 2003;89:S3-S8.
9. Edmonson JH, Su J, Krook JE. Treatment of ovarian cancer in elderly women. Mayo Clinic-North Central Cancer Treatment Group Studies. Cancer 1993;71:615-617.
10. Balducci L, Hardy CL, Lyman GH: Hemopoietic reserve in the older cancer patient: Clinical and economical considerations. Cancer Control 2000;7:539-547.
11. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-871.
12. Harter P, du Bois A, Schade-Brittinger C et al. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol 2005;16:1801-1805.
13. Markman M, Lewis JL Jr, Saigo P et al. Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center Experience. Cancer 1993;71:634-637.
14. Oriel LG, Hartenbach EM, Remington OL. Trends in United States ovarian cancer mortality, 1979-1995. Obstet Gynecol 1999;93:30-33.
15. Hershman D, Jacobson JS, McBride R et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 2004;94:540-549.
16. Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 2005;11:461-473.
17. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993;85:1580-1584.
18. Giovanazzi-Bannon S, Radermaker A, Lai G et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials; an Illinois Cancer Center Study. J Clin Oncol 1994;12:2447-2452.
19. Moore DH, Kauderer JT, Bell J, Curtin JP, Van Le L. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol 2004;94:368-374.
20. Maas HAAM, Kruitwagen RFPM, Lemmens VEPP, Goey SH, Janssen-Heijnen MLG. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 2005;97:104-109.
21. Cress RD, O'Malley CD, Leiserowitz GS, Campleman SL. Patterns of chemotherapy use for women with ovarian cancer: A population-based study. J Clin Oncol 2003;21:1530-1535.
22. Marchetti DL, Lele SB, Priore RL, McPhee ME, Hreshchyshyn MM. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol 1993;49:86-91.
23. Higgins RV, Naumann RW, Gardner J, Hall JB. Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin? Gynecol Oncol 1999;75:464-467.
24. Villella JA, Chaudhry T, Pearl ML et al. Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol 2002;86:316-322.
25. Bruchim I, Altaras M, Fishman A. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol 2002;86:274-8.
26. Petignat P, Fioretta G, Verkooijen HM et al. Poorer survival of elderly patients with ovarian cancer: A population-based study. Surg Oncol 2004;13:181-186.
27. Thigpen T, Brady MF, Omura GA et al. Age as a prognostic factor in ovarian cancer. The Gynecologic Oncology Group experience. Cancer 1993;71 (Suppl. 2):606-614.